GSK completes Novartis vaccines purchase; Galena announces positive PhIIb cancer vax results;

> GlaxoSmithKline ($GSK) completed its acquisition of Novartis' ($NVS) vaccine business. Story

> Galena Biopharma announced positive Phase IIa results of its GALE-301 immunotherapy in preventing the recurrence of ovarian and endometrial cancers. Galena also identified an optimal dose. Statement

> Aduro ($ADRO), through a $32 million purchase of Dutch biotech BioNovion, added an in-house preclinical pipeline of antibodies and checkpoint inhibitors. Report

> Researchers at the University of Rochester Medical Center received $3.1 million from the NIH to look for new ways to develop an HIV vaccine. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.